



ELSEVIER

Clinica Chimica Acta 300 (2000) 219–220



www.elsevier.com/locate/clinchim

Author index

Volume 300 (2000)

- Ali-Labib, R., see Eissa, S. 300, 159
Álvarez, E., see Ruiz-Pesini, E. 300, 97
Asa, S.L., see Magklara, A. 300, 171
Awadallah, S., see Hamad, M. 300, 75
- Bellik, B., see Houzé, P. 300, 181
Biddle, D.A., Datta, P., Wells, A., Dasgupta, A.,
Falsely elevated serum digitoxin concentrations
due to cross-reactivity of water-extractable di-
gitoxin-like immunoreactivity of Chinese medi-
cine Chan SU: elimination of interference by use
of a chemiluminescent assay 300, 151
Bouro, F., see Houzé, P. 300, 181
Bousquet, B., see Houzé, P. 300, 181
Bozzi, A., see D'Alessandro, A.M. 300, 119
Brguljan, P.M., see Cimerman, N. 300, 83
Brisdelli, F., see D'Alessandro, A.M. 300, 119
Brouet, J.C., see Houzé, P. 300, 181
- Chalmers, R.A., see Jones, M.G. 300, 203
Chan, D.W., see Green, G.B. 300, 57
Cheung, C.C., see Magklara, A. 300, 171
Cimerman, N., Brguljan, P.M., Krašovec, M.,
Šuškovič, S., Kos, J., Serum cystatin C, a potent
inhibitor of cysteine proteinases, is elevated in
asthmatic patients 300, 83
Cömlekci, A., see Kuralay, F. 300, 43
- D'Alessandro, A.M., Rinaldi, A.C., D'Andrea, G.,
Brisdelli, F., Di Ciccio, L., Di Giulio, A.,
Oratore, A., Bozzi, A., Evidences that
zidovudine (AZT) could not be directly respon-
sible for iron overload in AZT-treated patients:
an in vitro study 300, 119
D'Andrea, G., see D'Alessandro, A.M. 300, 119
Dasgupta, A., see Biddle, D.A. 300, 151
Datta, P., see Biddle, D.A. 300, 151
- Daxecker, H., see Heinschink, A. 300, 23
Dehlinger, E., see Green, G.B. 300, 57
De Iuliis, A., see Galzigna, L. 300, 131
Deuther-Conrad, W., see Franke, S. 300, 29
Di Ciccio, L., see D'Alessandro, A.M. 300, 119
Di Giulio, A., see D'Alessandro, A.M. 300, 119
Diamandis, E.P., see Magklara, A. 300, 171
Diamant, J., see Salazar, L.A. 300, 139
Díez, C., see Ruiz-Pesini, E. 300, 97
- Eissa, S., Ali-Labib, R., Khalifa, A., Deletion of
p16 and p15 genes In schistosomiasis-associated
bladder cancer (SABC) 300, 159
Elghetany, M.T., see Rao, L.V. 300, 13
Enríquez, J.A., see Ruiz-Pesini, E. 300, 97
Erwa, W., see Mangge, H. 300, 195
- Forti, N., see Salazar, L.A. 300, 139
Franke, S., Niwa, T., Deuther-Conrad, W., Sommer,
M., Hein, G., Stein, G., Immunochemical de-
tection of imidazolone in uremia and rheumatoid
arthritis 300, 29
- Gallistl, S., see Mangge, H. 300, 195
Galzigna, L., De Iuliis, A., Zanatta, L., Enzymatic
dopamine peroxidation in substantia nigra of
human brain 300, 131
Giannini, S.D., see Salazar, L.A. 300, 139
Green, G.B., Dehlinger, E., McGrievy, T.S., Li,
D.J., Jones, K.A., Kelen, G.D., Chan, D.W., CK-
MB isoforms for early risk stratification of
emergency department patients 300, 57
Griesmacher, A., see Heinschink, A. 300, 23
- Hamad, M., Awadallah, S., Age group-associated
variations in the pattern of Hp type distribution
in Jordanians 300, 75

- Hein, G., see Franke, S. 300, 29
- Heinschink, A., Raab, M., Daxecker, H., Griesmacher, A., Müller, M.M., In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes 300, 23
- Herrmann, J., see Mangge, H. 300, 195
- Hirata, M.H., see Salazar, L.A. 300, 139
- Hirata, R.D.C., see Salazar, L.A. 300, 139
- Houzé, P., Bellik, B., Brouet, J.C., Bouro, F., Bousquet, B., Comparison of urinary markers for bone resorption in multiple myeloma 300, 181
- Jones, K.A., see Green, G.B. 300, 57
- Jones, M.G., Chalmers, R.A., Artefacts in organic acid analysis: occurrence and origin of partially trimethylsilylated 3-hydroxy-3-methyl carboxylic acids 300, 203
- Kelen, G.D., see Green, G.B. 300, 57
- Khalifa, A., see Eissa, S. 300, 159
- Komosinska-Vashev, K., Olczyk, K., Kucharz, E.J., Marcisz, C., Winsz-Szczotka, K., Kotulska, A., Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy 300, 107
- Kos, J., see Cimerman, N. 300, 83
- Kotulska, A., see Komosinska-Vashev, K. 300, 107
- Krašovec, M., see Cimerman, N. 300, 83
- Kucharz, E.J., see Komosinska-Vashev, K. 300, 107
- Kuralay, F., Tokgöz, Z., Cömleki, A., Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin 300, 43
- Lapeña, A.C., see Ruiz-Pesini, E. 300, 97
- Li, D.J., see Green, G.B. 300, 57
- Liebmann, P., see Mangge, H. 300, 195
- Lima, T.M., see Salazar, L.A. 300, 139
- López-Pérez, M.J., see Ruiz-Pesini, E. 300, 97
- Magklara, A., Cheung, C.C., Asa, S.L., Diamandis, E.P., Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland 300, 171
- Mangge, H., Liebmann, P., Tanil, H., Herrmann, J., Wagner, C., Gallistl, S., Schauenstein, K., Erwa, W., Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis 300, 195
- Marcisz, C., see Komosinska-Vashev, K. 300, 107
- McGrievy, T.S., see Green, G.B. 300, 57
- Müller, M.M., see Heinschink, A. 300, 23
- Niwa, T., see Franke, S. 300, 29
- Okorodudu, A.O., see Rao, L.V. 300, 13
- Olczyk, K., see Komosinska-Vashev, K. 300, 107
- Oratore, A., see D'Alessandro, A.M. 300, 119
- Patel, V.B., Richardson, P.J., Preedy, V.R., Inability of propranolol to prevent alcohol-induced reductions in cardiac protein synthesis in vivo 300, 1
- Petersen, J.R., see Rao, L.V. 300, 13
- Preedy, V.R., see Patel, V.B. 300, 1
- Raab, M., see Heinschink, A. 300, 23
- Rao, L.V., Okorodudu, A.O., Petersen, J.R., Elghetany, M.T., Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions 300, 13
- Richardson, P.J., see Patel, V.B. 300, 1
- Rinaldi, A.C., see D'Alessandro, A.M. 300, 119
- Ruiz-Pesini, E., Lapeña, A.C., Díez, C., Álvarez, E., Enríquez, J.A., López-Pérez, M.J., Seminal quality correlates with mitochondrial functionality 300, 97
- Salazar, L.A., Hirata, M.H., Giannini, S.D., Forti, N., Diamant, J., Lima, T.M., Hirata, R.D.C., Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease 300, 139
- Schauenstein, K., see Mangge, H. 300, 195
- Sommer, M., see Franke, S. 300, 29
- Stein, G., see Franke, S. 300, 29
- Šuškovič, S., see Cimerman, N. 300, 83
- Tanil, H., see Mangge, H. 300, 195
- Tokgöz, Z., see Kuralay, F. 300, 43
- Tsuboi, I., Interleukin-1 α antisense oligomer suppresses hepatocyte growth 300, 213
- Wagner, C., see Mangge, H. 300, 195
- Wells, A., see Biddle, D.A. 300, 151
- Winsz-Szczotka, K., see Komosinska-Vashev, K. 300, 107
- Zanatta, L., see Galzigna, L. 300, 131



Subject index

Volume 300 (2000)

- AZT**; Zidovudine; Iron chelation; Iron overload; Transferrin; Transferrin receptor; K562 cells; Calcein **300**, 119
- Activated partial thromboplastin time**; Coagulation testing; Prothrombin time; Stability; Storage; Pre-transport temperature requirements **300**, 13
- Activation markers**; Mycophenolic acid; Cell cycle **300**, 23
- Advanced glycation end-product**; Imidazolone; 3-Deoxyglucosone; β_2 -microglobulin; Chronic renal failure; Rheumatoid arthritis **300**, 29
- Age group**; Hp; Phenotype; Allele frequency; Jordan **300**, 75
- Alcohol**; Heart; Male Wistar rat; β -Blocker **300**, 1
- Allele frequency**; Hp; Phenotype; Age group; Jordan **300**, 75
- Angiography**; Candidate genes; Genetic polymorphism; Coronary artery disease; Atherosclerosis **300**, 139
- Antioxidants**; Graves' disease; Lipid peroxidation; Protein oxidation **300**, 107
- Antisense oligome**; Interleukin-1 α ; Hepatocyte **300**, 213
- Artefacts**; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC-MS; Trimethylsilylation **300**, 203
- Asthma**; Cystatin C; Creatinine; Serum; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83
- Atherosclerosis**; Candidate genes; Genetic polymorphism; Coronary artery disease; Angiography **300**, 139
- Bisphosphonates**; Carboxyterminal telopeptide; Total pyridinolines; Multiple myeloma **300**, 181
- Bladder cancer**; Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; SCC; Schistosomiasis. **300**, 159
- β -Blocker**; Heart; Alcohol; Male Wistar rat **300**, 1
- CK-MB**; Isoforms; Emergency department; Ischemia; Risk; Chest pain **300**, 57
- Calcein**; AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; Transferrin receptor; K562 cells **300**, 119
- Candidate genes**; Genetic polymorphism; Coronary artery disease; Atherosclerosis; Angiography **300**, 139
- Carbohydrate antigen-125**; Pleural effusion; Carbohydrate antigen-19.9; Neuron specific enolase; Mucinous-carcinoma-associated antigen; Ferritin **300**, 43
- Carbohydrate antigen-19.9**; Pleural effusion; Carbohydrate antigen-125; Neuron specific enolase; Mucinous-carcinoma-associated antigen; Ferritin **300**, 43

- Carboxyterminal telopeptide**; Total pyridinolines; Multiple myeloma; Bisphosphonates **300**, 181
- Cell cycle**; Mycophenolic acid; Activation markers **300**, 23
- Chan SU**; Digitoxin; Fluorescence polarization immunoassay; Chemiluminescent immunoassay **300**, 151
- Chemiluminescent immunoassay**; Digitoxin; Chan SU; Fluorescence polarization immunoassay **300**, 151
- Chest pain**; CK-MB; Isoforms; Emergency department; Ischemia; Risk **300**, 57
- Chronic renal failure**; Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; β_2 -microglobulin; Rheumatoid arthritis **300**, 29
- Coagulation testing**; Prothrombin time; Activated partial thromboplastin time; Stability; Storage; Pre-transport temperature requirements **300**, 13
- Coronary artery disease**; Candidate genes; Genetic polymorphism; Atherosclerosis; Angiography **300**, 139
- Creatinine**; Asthma; Cystatin C; Serum; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83
- Cyclin dependent kinase inhibitors**; Tumor suppressor gene; p15; p16; Bladder cancer; SCC; Schistosomiasis. **300**, 159
- Cyclosporin A**; Asthma; Cystatin C; Creatinine; Serum; 24-h variations; Methylprednisolone **300**, 83
- Cystatin C**; Asthma; Creatinine; Serum; 24-h variations; Cyclosporin A; Methylprednisolone **300**, 83
- Cystatin C**; Prolonged RA; Early renal damage; Diagnosis **300**, 195
- 3-Deoxyglucosone**; Advanced glycation end-product; Imidazolone; β_2 -microglobulin; Chronic renal failure; Rheumatoid arthritis **300**, 29
- Diagnosis**; Prolonged RA; Early renal damage; Cystatin C **300**, 195
- Digitoxin**; Chan SU; Fluorescence polarization immunoassay; Chemiluminescent immunoassay **300**, 151
- Dopamine**; Substantia nigra; Parkinson's disease; Dopaminochrome; Peroxidase; Melanin; Neuroblastoma cells **300**, 131
- Dopaminochrome**; Substantia nigra; Parkinson's disease; Dopamine; Peroxidase; Melanin; Neuroblastoma cells **300**, 131
- Early renal damage**; Prolonged RA; Diagnosis; Cystatin C **300**, 195
- Emergency department**; CK-MB; Isoforms; Ischemia; Risk; Chest pain **300**, 57
- Ferritin**; Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Neuron specific enolase; Mucinous-carcinoma-associated antigen **300**, 43
- Fluorescence polarization immunoassay**; Digitoxin; Chan SU; Chemiluminescent immunoassay **300**, 151
- GC-MS**; 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; Trimethylsilylation; Artefacts **300**, 203
- Gene expression**; Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Thyroid cancer; Non-prostatic PSA **300**, 171
- Genetic polymorphism**; Candidate genes; Coronary artery disease; Atherosclerosis; Angiography **300**, 139
- Graves' disease**; Lipid peroxidation; Protein oxidation; Antioxidants **300**, 107
- Heart**; Alcohol; Male Wistar rat; β -Blocker **300**, 1
- Hepatocyte**; Interleukin-1 α ; Antisense oligome **300**, 213
- Hp**; Phenotype; Allele frequency; Age group; Jordan **300**, 75
- Human glandular kallikrein 2 (hK2)**; Prostate-specific antigen (PSA); Kallikreins; Thyroid; Thyroid cancer; Non-prostatic PSA; Gene expression **300**, 171

- 3-Hydroxy-3-methylglutaric acid;** 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC-MS; Trimethylsilylation; Artefacts **300, 203**
- 3-Hydroxy-3-methylglutaryl CoA lyase deficiency;** 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; GC-MS; Trimethylsilylation; Artefacts **300, 203**
- 3-Hydroxyisovaleric acid;** 3-Hydroxy-3-methylglutaric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC-MS; Trimethylsilylation; Artefacts **300, 203**
- Imidazolone;** Advanced glycation end-product; 3-Deoxyglucosone; β_2 -microglobulin; Chronic renal failure; Rheumatoid arthritis **300, 29**
- Interleukin-1 α ;** Antisense oligome; Hepatocyte **300, 213**
- Iron chelation;** AZT; Zidovudine; Iron overload; Transferrin; Transferrin receptor; K562 cells; Calcein **300, 119**
- Iron overload;** AZT; Zidovudine; Iron chelation; Transferrin; Transferrin receptor; K562 cells; Calcein **300, 119**
- Ischemia;** CK-MB; Isoforms; Emergency department; Risk; Chest pain **300, 57**
- Isoforms;** CK-MB; Emergency department; Ischemia; Risk; Chest pain **300, 57**
- Jordan;** Hp; Phenotype; Allele frequency; Age group **300, 75**
- K562 cells;** AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; Transferrin receptor; Calcein **300, 119**
- Kallikreins;** Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Thyroid; Thyroid cancer; Non-prostatic PSA; Gene expression **300, 171**
- Lipid peroxidation;** Graves' disease; Protein oxidation; Antioxidants **300, 107**
- Male Wistar rat;** Heart; Alcohol; β -Blocker **300, 1**
- Melanin;** Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Peroxidase; Neuroblastoma cells **300, 131**
- Methylprednisolone;** Asthma; Cystatin C; Creatinine; Serum; 24-h variations; Cyclosporin A **300, 83**
- β_2 -microglobulin;** Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; Chronic renal failure; Rheumatoid arthritis **300, 29**
- Mitochondria;** Oligozoospermia; OXPHOS; Spermatogenesis; Spermatozoa **300, 97**
- Mucinous-carcinoma-associated antigen;** Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Neuron specific enolase; Ferritin **300, 43**
- Multiple myeloma;** Carboxyterminal telopeptide; Total pyridinolines; Bisphosphonates **300, 181**
- Mycophenolic acid;** Activation markers; Cell cycle **300, 23**
- Neuroblastoma cells;** Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Peroxidase; Melanin **300, 131**
- Neuron specific enolase;** Pleural effusion; Carbohydrate antigen-19.9; Carbohydrate antigen-125; Mucinous-carcinoma-associated antigen; Ferritin **300, 43**
- Non-prostatic PSA;** Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Thyroid cancer; Gene expression **300, 171**
- OXPHOS;** Mitochondria; Oligozoospermia; Spermatogenesis; Spermatozoa **300, 97**
- Oligozoospermia;** Mitochondria; OXPHOS; Spermatogenesis; Spermatozoa **300, 97**
- p15;** Cyclin dependent kinase inhibitors; Tumor suppressor gene; p16; Bladder cancer; SCC; Schistosomiasis. **300, 159**
- p16;** Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; Bladder cancer; SCC; Schistosomiasis. **300, 159**

- Parkinson's disease;** Substantia nigra; Dopaminochrome; Dopamine; Peroxidase; Melanin; Neuroblastoma cells **300, 131**
- Peroxidase;** Substantia nigra; Parkinson's disease; Dopaminochrome; Dopamine; Melanin; Neuroblastoma cells **300, 131**
- Phenotype;** Hp; Allele frequency; Age group; Jordan **300, 75**
- Pleural effusion;** Carbohydrate antigen-19.9; Carbohydrate antigen-125; Neuron specific enolase; Mucinous-carcinoma-associated antigen; Ferritin **300, 43**
- Pre-transport temperature requirements;** Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Stability; Storage **300, 13**
- Prolonged RA;** Early renal damage; Diagnosis; Cystatin C **300, 195**
- Prostate-specific antigen (PSA);** Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Thyroid cancer; Non-prostatic PSA; Gene expression **300, 171**
- Protein oxidation;** Graves' disease; Lipid peroxidation; Antioxidants **300, 107**
- Prothrombin time;** Coagulation testing; Activated partial thromboplastin time; Stability; Storage; Pre-transport temperature requirements **300, 13**
- Rheumatoid arthritis;** Advanced glycation end-product; Imidazolone; 3-Deoxyglucosone; β_2 -microglobulin; Chronic renal failure **300, 29**
- Risk;** CK-MB; Isoforms; Emergency department; Ischemia; Chest pain **300, 57**
- SCC;** Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; Bladder cancer; Schistosomiasis. **300, 159**
- Schistosomiasis;** Cyclin dependent kinase inhibitors; Tumor suppressor gene; p15; p16; Bladder cancer; SCC **300, 159**
- Serum;** Asthma; Cystatin C; Creatinine; 24-h variations; Cyclosporin A; Methylprednisolone **300, 83**
- Spermatogenesis;** Mitochondria; Oligozoospermia; OXPHOS; Spermatozoa **300, 97**
- Spermatozoa;** Mitochondria; Oligozoospermia; OXPHOS; Spermatogenesis **300, 97**
- Stability;** Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Storage; Pre-transport temperature requirements **300, 13**
- Storage;** Coagulation testing; Prothrombin time; Activated partial thromboplastin time; Stability; Pre-transport temperature requirements **300, 13**
- Substantia nigra;** Parkinson's disease; Dopaminochrome; Dopamine; Peroxidase; Melanin; Neuroblastoma cells **300, 131**
- Thyroid cancer;** Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid; Non-prostatic PSA; Gene expression **300, 171**
- Thyroid;** Prostate-specific antigen (PSA); Human glandular kallikrein 2 (hK2); Kallikreins; Thyroid cancer; Non-prostatic PSA; Gene expression **300, 171**
- Total pyridinolines;** Carboxyterminal telopeptide; Multiple myeloma; Bisphosphonates **300, 181**
- Transferrin receptor;** AZT; Zidovudine; Iron chelation; Iron overload; Transferrin; K562 cells; Calcein **300, 119**
- Transferrin;** AZT; Zidovudine; Iron chelation; Iron overload; Transferrin receptor; K562 cells; Calcein **300, 119**
- Trimethylsilylation;** 3-Hydroxy-3-methylglutaric acid; 3-Hydroxyisovaleric acid; 3-Hydroxy-3-methylglutaryl CoA lyase deficiency; GC-MS; Artefacts **300, 203**
- Tumor suppressor gene;** Cyclin dependent kinase inhibitors; p15; p16; Bladder cancer; SCC; Schistosomiasis. **300, 159**
- 24-h variations;** Asthma; Cystatin C; Creatinine; Serum; Cyclosporin A; Methylprednisolone **300, 83**
- Zidovudine;** AZT; Iron chelation; Iron overload; Transferrin; Transferrin receptor; K562 cells; Calcein **300, 119**